Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6993-6995

  Jung, Dong Sik ^a,b   Tverdek, Frank P ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Dong A University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE; ANTIFUNGAL AGENT; SUSPENSION; TABLET; TRIAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN; LEUKEMIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MYCOSIS; SUSPENSION; SYSTEMIC MYCOSIS; TABLET; ADVERSE EFFECTS; COMPARATIVE STUDY; COMPLICATION; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; LIVER; MICROBIOLOGY; MIDDLE AGED; MYCOSES; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIFUNGAL AGENTS; FEMALE; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL ABSORPTION; HUMANS; LEUKEMIA; LIVER; MALE; MIDDLE AGED; MYCOSES; SUSPENSIONS; TABLETS; TRIAZOLES;

EID: 84908577567     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04035-14     Document Type: Article

References (12)

1. Leventakos K, Lewis RE, Kontoyiannis DP. 2010. Fungal infections in leukemia patients: how do we prevent and treat them? Clin. Infect. Dis. 50:405-415. http://dx.doi.org/10.1086/649879.
2. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik J-AH, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12. http://dx.doi.org/10.1086/508774.
3. Krishna G, Ma L, Martinho M, O'Mara E. 2012. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob. Agents Chemother. 56:4196-4201. http://dx.doi.org/10.1128/AAC.00222-12.
4. Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. 2012. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single-And multiple-dose pharmacokinetics and safety in healthy volunteers. J. Antimicrob. Chemother. 67:2725-2730. http://dx.doi.org/10.1093/jac/dks268.
5. Kraft WK, Chang P, van Iersel ML, Waskin H, Krishna G, Kersemaekers W. 2014. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob. Agents Chemother. 58:4020-4025. http://dx.doi.org/10.1128/AAC.02448-13.
6. Duarte RF, López Jiménz J, Cornely OA, Ma L, van Iersel MPS, Waskins H. 2012. Phase 1B study of the pharmacokinetics and safety of posaconazole (POS) solid oral tablet in patients at risk for invasive fungal infection (IFI), abstr. A-1934. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother.
7. Shen JX, Krishna G, Hayes RN. 2007. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J. Pharm. Biomed. Anal. 43:228-236. http://dx.doi.org/10.1016/j.jpba.2006.06.011.
8. Heinz WJ, Zirkel J, Kuhn A, Schirmer D, Lenker U, Keller D, Klinker H. 2011. Relevance of timing for determination of posaconazole plasma concentrations. Antimicrob. Agents Chemother. 55:3621-3623. http://dx.doi.org/10.1128/AAC.00062-11.
9. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. 2014. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J. Antimicrob. Chemother. 69:1162-1176. http://dx.doi.org/10.1093/jac/dkt508.
10. National Cancer Institute. 2009. Common terminology criteria for adverse events (CTCAE), v4.0. National Cancer Institute, Bethesda, MD.
11. Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. 2012. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob. Agents Chemother. 56:5503-5510. http://dx.doi.org/10.1128/AAC .00802-12.
12. Crombag MR, Huisman C, Kemper EM, Bruggemann R, Bijleveld YA. 2012. Posaconazole treatment in hematologic patients: a pilot study of therapeutic drug monitoring. Ther. Drug Monit. 34:320-325. http://dx.doi.org/10.1097/FTD.0b013e31824d135c.